D
egenerative cervical myelopathy (DCM), a degenerative disease of the cervical spine, is the most common cause of spinal dysfunction worldwide.
1,2 Common symptoms include numb or clumsy hands, difficulty walking, sensory changes of the lower extremities, and neck pain. 3 Decompressive surgery has been shown to be safe and effective in the spectrum of disease severity in patients with mild, moderate, and severe neurologic impairment. 4, 5 However, studies have suggested residual disability after treatment in patients with more severe disease presentation. 4 Occasionally, patients present with significant neurologic deficiencies and very severe disease symptoms. In these cases, decompressive surgery is the treatment of choice. Although studies have shown surgery to be safe and effective in the treatment of patients with DCM, there is a paucity in literature concerning the efficacy of surgery in patients with very severe myelopathy. Clinical outcomes among patients with very severe DCM have only been specifically reported in small studies or included without differentiation in larger cohorts. Scardino et al 6 reported on nine patients with a Nurick grade of 5 or more. Fehlings et al 4 described outcomes of 83 patients with modified Japanese Orthopaedic Association (mJOA) score of 11 or less. Acharya et al 7 described outcomes in 21 patients with Nurick grade 3 or more. Fehlings et al 5 and Acharya et al 7 did not differentiate outcomes in patients with very severe preoperative symptomatology. 7 The aim of this study was to evaluate and present the outcomes of decompressive surgery in patients with very severe DCM (mJOA 8) in comparison to patients with severe DCM (mJOA 11).
MATERIALS AND METHODS

Patient Population
Data were obtained after a preplanned merger of two prospective observational studies conducted under the same investigational protocol, the CSM-North America (CSM-NA) study (clinicaltrial.gov NCT00285337) and the CSM-International (CSM-I) study (clinicaltrial.gov NCT00565734). Between December 2005 and January 2011, 757 patients (278 in the CSM-NA and 479 in the CSM-I study) were enrolled at 26 sites.
Key inclusion criteria included age 18 years or older, symptomatic DCM (secondary to either disc herniation, ossification of the posterior longitudinal ligament, ligamentum flavum hypertrophy, spondylosis, subluxation, congenital stenosis, or a combination of these changes), objective cervical cord compression (determined by magnetic resonance imaging [MRI]), no prior surgical treatment for myelopathy, and the absence of symptomatic lumbar stenosis.
Patients with severe disease were those with preoperative mJOA score of 11 or less. 8 We divided this group of patients into two cohorts, those with very severe disease (mJOA score 8 or less) and those with severe disease (mJOA score 9-11, inclusive). 6, 9 Of 254 patients in the sample, one patient died and five patients withdrew their consent before the first follow-up visit at 6 months and were excluded from the study. The follow-up rates among the remaining 248 patients were 86.3%, 82.45%, and 76.47% at 6-, 12-, and 24-month follow-up visits, respectively.
Ethical approval was obtained from each site. All participating patients provided verbal and written informed consent.
Surgical Techniques
All participants underwent anterior and/or posterior surgical decompression of the cervical spine. The choice of surgical approach, number of levels decompressed, and the option for instrumentation was left to the discretion of the attending surgeon.
Data Collection and Quality Assurance
For each participant, data were collected on demographics, neurological presentation, medical history, causative pathology, surgical summary, severity, disability, and health-related quality of life. Data were obtained preoperatively and at 6-, 12-, and 24-months postoperatively using electronic case report forms. Adverse events and complications were documented using standardized forms with a predetermined list of anticipated complications as well as an ''other'' option. Adverse events were adjudicated by a panel of investigators and classified as either related to DCM, related to surgery, or unrelated to either. External monitors performed both on-and off-site monitoring to confirm compliance with study protocol and to ensure that the data were authentic, accurate, and complete.
Outcome Measures
Validated functional assessment tools and quality of life questionnaires were used to evaluate preoperative and postoperative status. These included the mJOA scale, 10 Nurick scale, 11 Neck Disability Index (NDI), 12, 13 and the Short Form-36 version 2 (SF-36v2).
14 The mJOA and Nurick scales are clinician-administered DCM-specific measures of impairment and disease severity, whereas the NDI and SF-36v2 are patient-reported questionnaires that evaluate functional disability and overall health status, respectively. The mJOA allocates points between 0 (worst) and 18 (best) based on motor dysfunction of the upper and lower extremities, sensory impairment of the upper extremity, and sphincter dysfunction. The Nurick scale is a six-grade ordinal scale primarily based on gait dysfunction, and ranges from 0 (best) to 5 (worst). The NDI, a modification of the Oswestry Disability Index, is a self-reported, disease-specific, and reliable measure of disability that evaluates performance in ten different categories, including personal care, sleep, and driving; this score ranges from 0 (best) to 100% (worst). The SF-36v2 is a widely used health status survey that assesses physical component summary (PCS) and mental component summary (MCS); these scores were calculated using the 1998 US norms. The minimum clinically important differences have been established for the mJOA (1.1), SF-36v2 PCS (4.1), SF-36v2 MCS (5.7), and NDI (7.5) in a degenerative spine population but not for the Nurick grades, 12, 15, 16, 17 Analysis Differences in baseline characteristics and surgical details were compared between the two severity cohorts using t test and the Fisher exact test for quantitative and qualitative variables, respectively. Missing follow-up scores were imputed by a combination of last value carry forward and last value carry backwards approaches. Baseline scores were not used in imputation. After imputation, data were available for 231 (93.1%) patients. Using the imputed data, patient outcomes at 6-, 12-, and 24-month follow-up were compared between the severe and very severe cohorts using the general linear model (GLM) procedure available in SAS Version 9.4 (SAS Institute Inc., Cary, NC) constructing a two-way repeated measure Analysis of Variance (r-ANOVA) and two-way repeated measures Analysis of Covariance models. The dependent variables were baseline scores and three (6-, 12-, 24-month) follow-up scores (mJOA, Nurick, NDI, SF-36v2 PCS, and SF-36v2 MCS). The r-ANOVA included a repeated visit factor, a cohort factor (severe and very severe), and an interaction term between the visit and the cohort factors. The r-ANOVA is the unadjusted analysis. In the adjusted model (repeated measures Analysis of Covariance), the patient, disease severity, and surgical characteristics were controlled for, including sex, age, logarithm of duration of symptoms, smoking status, years of education, source(s) of stenosis (spondylosis, intervertebral disc, ossification of the posterior longitudinal ligament, ligamentum flavum hypertrophy, congenital stenosis, subluxation), affected cervical level(s), comorbidities by body system (cardiovascular, respiratory, gastrointestinal, renal, endocrine, psychiatric, rheumatologic, and neurological), duration of operation, and surgical approach. Only the covariates with a P value of less than 0.20 were kept in the model. Post-hoc between-cohort comparisons were adjusted for multiplicity using the Bonferroni correction. The study had 99% power to detect a difference of 1.1 (minimum clinically important differences) and 80% power to detect difference of 0.7 in the mJOA between the two cohorts based on an observed standard deviation (SD) of 1.684. An unadjusted sensitivity analysis was performed using nonimputed data.
All statistical analyses were performed using SAS/STAT version 9.4 (SAS Institute Inc.).
RESULTS
Demographics and Patient Characteristics
There were 188 patients in the severe cohort with baseline mJOA score between 9 and 11, and 60 patients in the very severe cohort with baseline mJOA score of 8 or less. The two cohorts were similar in demographics, duration of myelopathy symptoms, and disease characteristics (Table 1) . Surgical approaches used to decompress the spine were similar between the two cohorts. The very severe patient cohort had more affected levels compared to the severe patient cohort (4.30 vs. 3.94, P ¼ 0.0671) and longer duration of hospital stay (14.43 vs. 9.66 days, P ¼ 0.0097).
Baseline Status
Preoperatively, patients with very severe disease had worse clinical (mJOA and Nurick) and functional status measured by NDI. The average mJOA in the very severe cohort was 6.93 (SD ¼ 1.30, range 3-8); the average mJOA in the severe cohort was 10.22 (SD ¼ 0.77, range 9-11). There were no differences in health-related quality of life status measured by SF-36v2 PCS and MCS between the cohorts (Table 2) .
Clinical and Patient Outcomes
The mJOA outcomes improved after surgery for both subgroups (P < 0.0001). The bulk of improvement was obtained by 6 months postoperatively. Although further nominal improvement occurred after 6 months, it was not significant (Table 3, Figure 1 A) . The extent of improvement was larger in the very severe cohort compared to the severe cohort (follow-up visitÃgroup interaction < 0.0001). However, despite a greater improvement, the average score in very severe patients remained smaller compared to severe patients at all follow-ups. The adjusted analysis confirmed the same pattern (Table 4) . Patients with a longer duration of symptoms had poorer treatment response compared to those with a shorter duration of symptoms (P ¼ 0.0059). Furthermore, the effect of duration of symptoms was more pronounced in patients with very severe disease compared to those with severe disease.
The Nurick grades improved after surgery (P < 0.0001). Most improvement was obtained by 12 months postoperatively (Table 3 , Figure 1B ). The extent of improvement was greater in the very severe cohort compared to the severe cohort (follow-up visitÃgroup interaction P ¼ 0.0256). At 24 months follow-up, Nurick grade was better in the severe cohort compared to the very severe cohort in the unadjusted analysis, but not in the adjusted analysis (Table 4) .
At baseline, functional limitations measured by NDI scores were worse in the very severe cohort compared to the severe cohort (P ¼ 0.0034). NDI scores improved after surgery in both cohorts (<0.0001). The extent of improvement was greater in the very severe cohort compared to the severe cohort (follow-up visitÃcohort interaction P ¼ 0.0243). There were no differences in the score between the cohorts at any follow-up ( Figure 1C) . SF-36v2 PCS scores and SF-36v2 MCS scores improved in both cohorts (P < 0.0001). There were no differences between the cohorts at baseline or any of the follow-up visits. The findings remained the same after adjustment for covariates. Sensitivity analysis using nonimputed data did not differ from the findings of the imputed analysis (Figure 1  D, E) .
At 24 months follow-up, 35.85% patients in the very severe cohort had mild disease severity, 30.19% had moderate disease severity, and 33.96% still had severe disease. For the patients in the severe disease cohort, 44.38%, 33.71%, and 21.91% had mild, moderate, and severe symptoms at 24 months follow-up, respectively (P ¼ 0.2177).
In the very severe cohort, one patient (1.89%) had worsening symptoms and one patient (1.89%) did not improve. The remaining 51 patients (96.23%) improved for at least one point on the mJOA scale (range 1-14 points). Of those, six patients (11.32%) were symptom-free. In the severe cohort, 14 (7.87%) experienced worsening symptoms, 11 (6.18%) remained the same, and the remaining 153 patients (85.96%) improved between 1 and 9 points. Of those, 23 (12.92%) were symptom free.
Complications
Six patients (3.19%) from the severe cohort and three patients (5.0%) from the very severe cohort required subsequent surgery (P ¼ 0.4552). Fifty patients (26.60%) from the severe cohort and 12 (20%) patients in the very severe cohort had one or more complications. The most common complications were dysphagia (6.05%) and superficial infection (3.7%) ( Table 5 ).
DISCUSSION
Patients with very severe degenerative cervical myelopathy (mJOA 8) benefit from surgical intervention. There were improvements in clinical, functional, and health-related quality of life outcomes. These improvements are achieved at 6 months and sustained at 2 years, postoperatively. The extent of improvement in clinical and functional outcomes in patients with very severe disease exceeds the improvement in patients with severe disease. However, despite greater improvement, the follow-up mJOA and Nurick scores remained significantly lower in the very severe patients due to significantly lower preoperative scores. Very severe patients attained similar NDI functional outcomes and SF36v2 quality of life outcomes as did the patients with severe disease.
Although the extent of improvement is substantial, the patients with very severe disease endure significant residual symptoms and disability. Surgical treatment, although the most effective treatment modality, is not the cure of advanced DCM. In our study, at 2 years postoperative, approximately one third of the patients with very severe disease still had severe symptoms, one third had moderate symptoms, and one third had mild disease. Only about 1 in 10 patients were symptom-free. The average NDI was greater than 30 at all follow-ups. This underlines the challenges and limitations in the treatment of advanced DCM.
The very severe subcohort (mJOA 8) of patients with DCM represents a distinct cohort of patients and their different clinical trajectory is important for clinicians and patients to recognize. 18 The very severe patients utilize more treatment resources and have more residual symptomatology compared to severe patients. The economic impact of resource utilization and disability should be considered when prioritizing treatment.
Although there was a high rate of complications associated with surgical intervention, these appear to be transitory and with no significant impact on patient outcomes. There was no evidence of differences in complication rates between patients with very severe and those with severe disease.
There are important limitations to this study. First, this evaluation was based on a nonrandomized comparison study. Although extensive statistical adjustments were performed, there may have been confounding covariates unaccounted for in our statistical models. However, the authors believe it to be unlikely that the unadjusted confounding may affect any of the major conclusions of this study. Although the follow-up rate was high, outcome data from some patients were missing and were accounted for by imputation. A sensitivity analysis was performed to address this limitation.
In conclusion, decompressive surgery is effective in patients with very severe DCM, however, patients have significant residual symptoms and disability. Duration of symptoms negatively affects chances for recovery. Patients with DCM should be monitored accordingly and treated before developing very severe symptomatology. 
Key Points
Patients with very severe myelopathy benefit from surgical intervention. According to our results, having a longer duration of symptoms correlated with a poorer treatment response.
Although there was a high rate of complications associated with surgical intervention, these appear to be transitory and have no significant impact on patient outcomes. Patients with DCM should be monitored accordingly and treated before developing very severe symptomatology.
